|
|
ABCA4 positive - Stargardt Disease5 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease6 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease5 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease0 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease1 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease2 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease1 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease0 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease1 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease0 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
ABCA4 positive - Stargardt Disease0 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.
PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21Jan 16, 2022
|
|
Ocular lymphoma - better following intravitreal methotrexate14 viewsVA improved from LP to 20/200 after 4 injections of methotrexateJan 06, 2022
|
|
Ocular Lymphoma - Flare up despite chemotherapy and radiation therapy - This was treated with intravitreal methotrexate12 viewsVision in the left eye has declined to LP in this image following ocular recurrence of lymphomaJan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)12 views67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)2 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)5 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)2 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)7 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)7 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)7 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)6 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)6 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)6 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Bilateral Diffuse Melanocytic Proliferation (BDUMP)7 views67 year old man
The patient started noticing dimming of the vision in November of 2020. He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021. The vision did not improve with the cataract surgery. On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss. The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss. He recalled that he started the nivolumab in October of 2020 and had vision loss starting then. A retinal evaluation showed subretinal fluid and vision loss. The peripheral vision and central vision were pretty good. The vision did seem to get better off the nivolumab. Then when the patient returned to Florida in September and now the vision is getting worse. The patient did not have any treatments in either eye. The patient is now off the oncology treatment. He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month. It was stopped because of a skin rash and reactions.
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.Jan 06, 2022
|
|
Lattice with tears - 3 months post-laser45 viewsDec 13, 2021
|
|
Lattice with tears - 3 months post-laser40 viewsDec 13, 2021
|
|
Old BRVO with venous MA - post-laser OCT Maps98 viewsOct 29, 2021
|
|
Old BRVO with venous MA - post-laser OCT Maps73 viewsOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision66 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision6 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision6 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision10 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision12 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision10 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision7 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision7 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision7 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision10 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision22 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision13 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin
VA 20/20 OU
2+ NS OU
ObservationOct 29, 2021
|
|
Idiopathic Iris Cyst16 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and othersOct 28, 2021
|
|
Idiopathic Iris Cyst14 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and othersOct 28, 2021
|
|
Idiopathic Iris Cyst15 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and othersOct 28, 2021
|
|
Idiopathic Iris Cyst9 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and othersOct 28, 2021
|
|
Idiopathic Iris Cyst9 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and othersOct 28, 2021
|
|
Idiopathic Iris Cyst12 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and othersOct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram12 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram12 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram8 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram9 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram8 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram9 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram9 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram6 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram8 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram8 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
Non-exudative wet AMD - OCT angiogram13 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16Oct 28, 2021
|
|
| 14607 files on 147 page(s) |
1 |
 |
|
|
|
|
|
|
|
|
|
